Skye Bioscience, Inc. SKYE
1.11 USD -0.11 (-9.02%)
Nov 4, 2026, 2:50 PM EST
1.11 Day range 1.30
1.11 52-week range 12.80
- YTD
- -81.50%
- 1 year
- -90.23%
- Market cap
- 4.91M
- EPS (ttm)
- -10.16
- Shares out
- 30.34M
- Forward P/E
- -2.27
- YTD return
- -81.50%
- 1-year return
- -90.23%
- Volume
- 34.14K
- Avg volume
- 90.83K
- Open
- 1.25
- Previous close
- 1.22
- Day's range
- 1.11 – 1.30
- 52-week range
- 1.11 – 12.80
- Beta
- 1.75
- Analysts
- Strong Buy
- Price target
- 18.00 (+1521.6%)
- Earnings date
- Mar 29, 2024
2Y -42.37 (-97.36%)
Key statistics
- Enterprise value
- 14.69M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.05
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -15.71M
- Total cash
- 67.41M
- Total debt
- 190.99K
- Return on equity
- -54.82%
- Short % of float
- 7.83%
- 50-day average
- 4.44
- 200-day average
- 7.74
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 18.00 +1521.6% upside
Now 1.11
- Target (low)
- 14.00
- Target (mean)
- 18.00
- Target (high)
- 21.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy3
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 29, 2024
Expected Mar 29, 2024. Consensus EPS estimate -0.285.
Financials — quick view
SKYE Revenue — quarterly 0
SKYE Net income — quarterly -10.79M
SKYE EPS — quarterly -2.16
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.26 | -0.22 | +0.04 | +15.38% |
| Aug 9, 2024 | Jun 1, 2024 | -0.20 | -0.20 | 0.00 | 0.00% |
| May 10, 2024 | Mar 1, 2024 | -0.16 | -0.18 | -0.02 | -12.50% |
| Mar 29, 2024 | Dec 1, 2023 | -0.38 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -3.17 | — | — |
| Aug 7, 2023 | Jun 1, 2023 | 0.00 | 0.00 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 2024 | Scotiabank | init | — | Sector Outperform |
| Sep 20, 2024 | Piper Sandler | reit | Overweight | Overweight |
| Sep 20, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Sep 10, 2024 | JMP Securities | init | — | Market Outperform |
| Sep 9, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Sep 6, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company is conducting a Phase 2 clinical trial in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- skyebioscience.com
News
5Am Partners Vii, Llc Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock 
Andrew Schwab Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock 
12 Health Care Stocks Moving In Wednesday's Intraday Session - 12 Health Care Stocks Moving In Monday's Pre-Market Session
Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move 
Skye Bioscience Enters Into Securities Purchase Agreement With Redmile Affiliate For Aggregate Purchase Price Of Up To $22M 
Skye Bioscience to Merge With Redx, Forming Fibrosis-Focused Fibrx Therapeutics 
Why HIVE Digital Technologies Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket 
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript 
Skye Bioscience To Acquire Redx Pharma; Combined Company To Operate As Fibrx Therapeutics With $125M Financing
Your note
Sign in to keep a note on SKYE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| 5AM PARTNERS VII, LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 12, 2024 | 0 |
| ARSENAULT KAITLYN MELANIE | Chief Financial Officer | Sale | Nov 17, 2024 | 166,342 |
| DHILLON PUNIT S | Chief Executive Officer | Sale | Nov 17, 2024 | 339,166 |
| DIEP TUAN TU | Officer | Sale | Nov 17, 2024 | 82,259 |
| EMERALD HEALTH SCIENCES, INC. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Feb 21, 2023 | 169,408,000 |
| GRAYSON PAUL A | Director | Sale | Nov 17, 2024 | 259,701 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| 5AM Venture Management, LLC | 35.32% | 9,913,168 | 26.07M | Sep 29, 2024 |
| Versant Venture Management, LLC | 7.15% | 2,007,704 | 5.28M | Sep 29, 2024 |
| Sphera Funds Management Ltd. | 5.57% | 1,563,522 | 4.11M | Sep 29, 2024 |
| Baker Bros. Advisors, LP | 5.11% | 1,434,634 | 3.77M | Sep 29, 2024 |
| Altium Capital Management, LP | 4.69% | 1,315,146 | 3.46M | Sep 29, 2024 |
| Blackrock Inc. | 4.25% | 1,193,515 | 3.14M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.70% | 477,100 | 1.25M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.59% | 446,814 | 1.18M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.89% | 249,751 | 656.85K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.63% | 176,099 | 463.14K | Aug 30, 2024 |
| AdvisorShares Trust-AdvisorShares Pure Cannabis ETF | 0.57% | 160,000 | 420.80K | Oct 30, 2024 |
| iShares Russell 2000 Value ETF | 0.49% | 136,819 | 359.83K | Oct 30, 2024 |